ATE490787T1 - Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion - Google Patents

Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion

Info

Publication number
ATE490787T1
ATE490787T1 AT04747833T AT04747833T ATE490787T1 AT E490787 T1 ATE490787 T1 AT E490787T1 AT 04747833 T AT04747833 T AT 04747833T AT 04747833 T AT04747833 T AT 04747833T AT E490787 T1 ATE490787 T1 AT E490787T1
Authority
AT
Austria
Prior art keywords
igm
production
quantifying
transformed cells
chain
Prior art date
Application number
AT04747833T
Other languages
English (en)
Inventor
Reiko Irie
Hiroyuki Tsunoda
Tomoyuki Igawa
Yasuo Sekimori
Masayuki Tsuchiya
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE490787T1 publication Critical patent/ATE490787T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT04747833T 2003-07-15 2004-07-15 Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion ATE490787T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48733303P 2003-07-15 2003-07-15
PCT/JP2004/010444 WO2005005636A1 (ja) 2003-07-15 2004-07-15 形質転換細胞によるIｇMの産生とその定量方法

Publications (1)

Publication Number Publication Date
ATE490787T1 true ATE490787T1 (de) 2010-12-15

Family

ID=34062150

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04747833T ATE490787T1 (de) 2003-07-15 2004-07-15 Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion

Country Status (9)

Country Link
US (2) US7709615B2 (de)
EP (2) EP2204190A1 (de)
JP (1) JP5452835B2 (de)
AT (1) ATE490787T1 (de)
AU (1) AU2004256354B2 (de)
CA (1) CA2532966C (de)
DE (1) DE602004030451D1 (de)
TW (1) TW200510532A (de)
WO (1) WO2005005636A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004256354B2 (en) * 2003-07-15 2011-07-07 Chugai Seiyaku Kabushiki Kaisha IgM production by transformed cells and methods for quantifying said IgM production
ATE518888T1 (de) * 2003-10-09 2011-08-15 Chugai Pharmaceutical Co Ltd Stabilisierte lösung mit hoher igm-konzentration
JP4671864B2 (ja) * 2003-10-09 2011-04-20 中外製薬株式会社 タンパク質溶液の安定化方法
JP4818936B2 (ja) * 2005-01-05 2011-11-16 中外製薬株式会社 細胞の培養方法およびその利用
WO2007002676A2 (en) * 2005-06-27 2007-01-04 Invitrogen Corporation Liquid protein markers for native gel electrophoresis
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
WO2007106617A2 (en) * 2006-01-30 2007-09-20 Talecris Biotherapeutics, Inc. Method of treatment and prophylaxis of diseases related to amyloid deposition using igm
PT2047863E (pt) 2006-06-08 2013-10-21 Chugai Pharmaceutical Co Ltd Prevenção ou tratamento para doença inflamatória
HU0700534D0 (en) 2006-11-24 2007-10-29 Mezoegazdasagi Biotechnologiai Transgenic animal with enhanced immune response and method for the preparation thereof
CN101802192A (zh) 2007-10-15 2010-08-11 中外制药株式会社 抗体的制备方法
BRPI0821145B8 (pt) 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo anti-nr10 como agente preventivo ou terapêutico para prurido
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
TWI466684B (zh) * 2008-06-30 2015-01-01 Morphotek Inc 抗ｇｄ２抗體及其相關方法及用途
EP2363148B1 (de) * 2008-10-31 2014-11-26 Japan Science and Technology Agency Verfahren zur selektiven steuerung der funktion von t-helferzellen
TWI505838B (zh) 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody solution containing
EP2735315B1 (de) 2011-07-19 2019-10-02 Chugai Seiyaku Kabushiki Kaisha Proteinhaltige stabile zubereitung mit argininamid oder valinamid
JP6363017B2 (ja) 2011-09-01 2018-07-25 中外製薬株式会社 限外ろ過によって高度に濃縮された抗体を含む組成物を調製するための方法
CA2870625C (en) * 2012-04-17 2023-06-20 Mayo Foundation For Medical Education And Research Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions
CA2888652C (en) * 2012-11-30 2020-09-22 Katinger Gmbh Recombinant human igm-antibody effective against cancer cells
WO2014093786A1 (en) * 2012-12-14 2014-06-19 Abbvie, Inc. Methods for increasing the efficiency of hybridoma generation
US10654933B2 (en) 2013-12-27 2020-05-19 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
HUE042829T2 (hu) 2014-04-03 2019-07-29 Igm Biosciences Inc Módosított J-lánc
WO2016027859A1 (ja) 2014-08-20 2016-02-25 中外製薬株式会社 蛋白質溶液の粘度測定方法
CA2972990A1 (en) 2015-01-20 2016-07-28 Beatrice Tien-Yi WANG Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
PL3265575T3 (pl) * 2015-03-04 2021-11-29 Igm Biosciences, Inc. Cząsteczki wiążące CD20 i ich zastosowania
CA2980751A1 (en) * 2015-03-25 2016-09-29 Stephen F. Carroll Multi-valent hepatitis b virus antigen binding molecules and uses thereof
CN108463472A (zh) 2015-09-30 2018-08-28 Igm生物科学有限公司 具有修饰的j-链的结合分子
AU2016329197B2 (en) 2015-09-30 2021-01-21 Igm Biosciences, Inc. Binding molecules with modified J-chain
US10572893B2 (en) 2016-06-16 2020-02-25 International Business Machines Corporation Discovering and interacting with proximate automobiles
CN112512480B (zh) 2018-05-21 2024-10-01 中外制药株式会社 被封入玻璃容器的冷冻干燥制剂
CN112243423B (zh) 2018-05-28 2022-11-04 中外制药株式会社 填充喷嘴
AU2020322031A1 (en) * 2019-07-31 2022-03-10 The Wistar Institute Of Anatomy And Biology Multivalent DNA antibody constructs and use thereof
CA3173414A1 (en) * 2020-04-22 2021-10-28 Bruce Keyt Pd-1 agonist multimeric binding molecules
US20240301064A1 (en) * 2021-02-23 2024-09-12 Pandion Operations, Inc. Pd-1 antibodies, polypeptides and uses thereof
WO2023064841A1 (en) * 2021-10-13 2023-04-20 The Wistar Institute Of Anatomy And Biology Antibodies for use against sars-cov-2

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
EP0303088B1 (de) 1987-08-10 1992-11-11 Miles Inc. Gereinigtes IgM
US5157113A (en) * 1987-08-10 1992-10-20 Miles Inc. Removal of nucleic acids from monoclonal antibody preparations
GB8719963D0 (en) * 1987-08-24 1987-09-30 Cattaneo A Recombinant dna products
CA1312030C (en) 1987-11-18 1992-12-29 Brian Maiorella Method to increase antibody titer
US6238891B1 (en) * 1987-11-18 2001-05-29 Cetus Oncology Corporation Method of increasing product expression through solute stress
JP2501116B2 (ja) 1988-03-05 1996-05-29 日本電信電話株式会社 巡回制御形回線交換方法
DE3825429C2 (de) 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
GB9010944D0 (en) 1990-05-16 1990-07-04 Central Blood Lab Authority Chemical compounds
US5419904A (en) * 1990-11-05 1995-05-30 The Regents Of The University Of California Human B-lymphoblastoid cell line secreting anti-ganglioside antibody
JPH05192181A (ja) 1990-12-18 1993-08-03 Ishihara Sangyo Kaisha Ltd ヒトモノクローナル抗体
EP0492409A1 (de) * 1990-12-18 1992-07-01 Ishihara Sangyo Kaisha, Ltd. Menschlicher monoklonaler Antikörper
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
AU660981B2 (en) * 1991-03-12 1995-07-13 Astellas Us Llc CD2-binding domain of lymphocyte function associated antigen 3
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
JPH04360696A (ja) * 1991-06-06 1992-12-14 Sumitomo Chem Co Ltd 新規なヒトｂリンパ細胞株を宿主として産生された組み換えヒト抗体
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
CA2105618C (en) * 1992-09-07 2009-11-03 Kazuyasu Nakamura Humanized antibodies to ganglioside gm2
JP3565572B2 (ja) 1992-09-07 2004-09-15 協和醗酵工業株式会社 ヒト化抗体
JPH06178689A (ja) * 1992-12-11 1994-06-28 Mitsui Toatsu Chem Inc Ｉ型緑膿菌を抗原とするヒト抗体をコードする遺伝子
JPH06189781A (ja) 1992-12-25 1994-07-12 Mitsui Toatsu Chem Inc 培養液中の生理活性タンパク質の安定化方法
JPH09127112A (ja) 1995-10-30 1997-05-16 Dainabotsuto Kk 修飾ＩｇＭ免疫学的測定試薬
JPH09127114A (ja) 1995-11-01 1997-05-16 Dainabotsuto Kk 免疫学的測定用安定化ＩｇＭ試薬
DE69730038T2 (de) * 1996-08-16 2004-11-25 The President And Fellows Of Harvard College, Cambridge Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
EP0835880A1 (de) 1996-10-14 1998-04-15 Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk Verfahren zur Herstellung eines IgM Präparates für die intravenöse Applikation
JPH10324699A (ja) * 1997-03-21 1998-12-08 Sankyo Co Ltd 抗ヒトＦａｓヒト化抗体
MY131805A (en) 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
WO1999036105A2 (en) 1998-01-16 1999-07-22 Mca Development B.V. USE OF RADIOLABELED MONOCLONAL IgM IN THERAPY FOR CANCER AND AUTOIMMUNE DISEASE
WO1999037329A1 (en) 1998-01-22 1999-07-29 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
CA2321262A1 (en) 1998-02-19 1999-08-26 President And Fellows Of Harvard College Monovalent, multivalent, and multimeric mhc binding domain fusion proteins and conjugates, and uses therefor
JP2000154149A (ja) * 1998-09-18 2000-06-06 Sankyo Co Ltd 抗ヒトＦａｓヒト化抗体含有抗リウマチ剤
DK1121382T3 (da) * 1998-10-16 2006-11-13 Biogen Idec Inc Interferon-beta-fusionsproteiner og deres anvendelser
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
WO2000066160A1 (fr) 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Composition medicamenteuse parenterale a fragment d'anticorps monoclonal humanise et procede de stabilisation
AU7449200A (en) 1999-09-30 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Derivatives of antibody against ganglioside gm2
AU1052701A (en) 1999-11-05 2001-06-06 Kyowa Hakko Kogyo Co. Ltd. Transgenic non-human mammals for monitoring change in calcium ion concentration in cells
PT2857516T (pt) * 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
WO2002003472A2 (en) 2000-06-29 2002-01-10 California Institute Of Technology Aerosol silicon nanoparticles for use in semiconductor device fabrication
WO2002010371A1 (fr) * 2000-08-01 2002-02-07 Kyowa Hakko Kogyo Co., Ltd. Peptide acitf sur le plan physiologique et utilisation de celui-ci
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
JP2003128576A (ja) * 2001-10-25 2003-05-08 Taisho Pharmaceut Co Ltd エンドトキシン誘発性疾患治療薬
AU2002356749A1 (en) * 2001-11-28 2003-06-10 Hermann Katinger Process for the production of polypeptides in mammalian cell cultures
DE10328295B4 (de) 2003-06-23 2007-11-22 Endress + Hauser Gmbh + Co. Kg Verfahren und entsprechende Vorrichtung zum Schweißen von Bauteilen eines Feldgerätes
US20070056262A1 (en) 2003-06-25 2007-03-15 Rachel Leach Laser propulsion thruster
AU2004256354B2 (en) 2003-07-15 2011-07-07 Chugai Seiyaku Kabushiki Kaisha IgM production by transformed cells and methods for quantifying said IgM production
ATE518888T1 (de) * 2003-10-09 2011-08-15 Chugai Pharmaceutical Co Ltd Stabilisierte lösung mit hoher igm-konzentration
JP4671864B2 (ja) 2003-10-09 2011-04-20 中外製薬株式会社 タンパク質溶液の安定化方法

Also Published As

Publication number Publication date
JP5452835B2 (ja) 2014-03-26
CA2532966A1 (en) 2005-01-20
US20070154469A1 (en) 2007-07-05
EP1652925A4 (de) 2007-07-04
CA2532966C (en) 2012-12-04
TWI342336B (de) 2011-05-21
TW200510532A (en) 2005-03-16
EP1652925A1 (de) 2006-05-03
US8257703B2 (en) 2012-09-04
US7709615B2 (en) 2010-05-04
WO2005005636A1 (ja) 2005-01-20
AU2004256354A1 (en) 2005-01-20
AU2004256354B2 (en) 2011-07-07
EP1652925B1 (de) 2010-12-08
US20100172899A1 (en) 2010-07-08
EP2204190A1 (de) 2010-07-07
DE602004030451D1 (de) 2011-01-20
JPWO2005005636A1 (ja) 2006-08-24

Similar Documents

Publication Publication Date Title
ATE490787T1 (de) Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion
ATE514717T1 (de) Rekombinante produktion von antikörpermischungen
HRP20130750T1 (hr) Postupak identifikacije molekula za vezanje koje mogu neutralizirati virus bjesnoä†e
EP1427445A4 (de) Verfahren zur reifung von plasmacytoiden dendritischen zellen unter verwendung von die immunantwort modifizierenden molekülen
DE60224643D1 (de) Verfahren zur herstellung von reifen
WO2004022714A3 (en) Organic species that facilitate charge transfer to or from nanostructures
ATE468314T1 (de) Verfahren zur herstellung von ameisensäure
ATE340174T1 (de) Verfahren zur umwandlung von dihidroisoxazol derivate in gamma-hydroxaminsäurederivate, z.b monatins
ATE489377T1 (de) Verfahren zur herstellung von 3-methylamino-1- (thien-2-yl)-propan-1-ol
DE602004020895D1 (de) Verfahren zur herstellung von kohlenstoffnanospulen
ATE457974T1 (de) Verfahren zur herstellung von phenylmalonsäure- dinitrilen
ATE458044T1 (de) Verfahren zur nukleinsäureamplifikation
ATE455778T1 (de) Verfahren zur herstellung form i von (s)-(+)- clopidogrelbisulfat
DE60321626D1 (de) Verfahren zur Herstellung von Acrylsäure
DE60331111D1 (de) Verfahren zur Herstellung von martensitaushärtendem Stahl
DE50302740D1 (de) Verfahren zur herstellung von verküpbaren organischen pigmenten
ATE336464T1 (de) Verfahren zur aufreinigung von blausäure
DE60331043D1 (de) Verfahren zur entfernung von dithiogruppen aus polymerkettenenden
DE60300356D1 (de) Ein Verfahren zur Trennung und Reinigung von RNA
DE602004000126D1 (de) Verfahren zur Herstellung von selbststanzenden Muttern
DE60200012D1 (de) Verfahren zur Herstellung von Luftreifen
DE60315741D1 (de) Verfahren zur Herstellung von Acrylsäure
ATE533837T1 (de) Microginin-produzierende proteine und nukleinsäuren, einen microginin gen-cluster kodierend, sowie methoden zur herstellung von microgininen
ATE359287T1 (de) Ein verfahren zur herstellung von clopidogrel
ATE548395T1 (de) Verfahren zur herstellung von polyolefinen in suspension

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties